Welcome!

News Feed Item

Foundation Venture Capital Group portfolio company, Snowdon, issued patents to treat pain and advance drug discovery

NEW BRUNSWICK, N.J., Jan. 31, 2014 /PRNewswire-USNewswire/ -- Drug discovery and development company Snowdon Inc., a Foundation Venture Capital Group portfolio company, has been issued two new patents to treat neuropathic pain and to expand its molecular search software tools.

The Glutamate Receptor Modulators and Therapeutics Agents patent (US #8614205) identifies a novel family of metabotropic glutamate receptor modulators as potential therapeutic agents for pain, neurological disorders and psychiatric illnesses.

According to company founder Dr. William Welsh, the Norman H. Edelman Professor in Bioinformatics at Rutgers Robert Wood Johnson Medical School, the Glutamate patent enables the use of simple molecules to treat neuropathic pain that arises from common medical conditions including diabetes, shingles, cancer, fibromyalgia, lower back pain and HIV/AIDS.

"Traditional pain medications are generally ineffective for treating neuropathic pain. We are hopeful the new treatments addressed in the patent can offer the hope of relief for millions of Americans suffering from this type of chronic pain," explained Dr. George F. Heinrich, vice chair and CEO of Foundation Venture Capital Group.

Snowdon's second patent (US #8200439) accelerates the discovery of new bioactive molecules, expanding the scope of a patent that Snowdon received in 2012.

"Our new fragment-based Shape Signatures software tool quickly and efficiently finds new molecules by searching our vast chemical libraries of more than 15 million entries," explained Dr. Welsh.

He says the fragment-based Shape Signatures approach works like a Lego toy that builds an assortment of objects by assembling interconnecting parts.  The fragment-based approach assembles smaller molecular fragments into novel, intact molecules that possess the desired biological activities.

Previously, Snowdon has advanced computer-guided drug discovery through collaboration with external partners such as the Department of Defense, the Environmental Protection Agency, the Food and Drug Administration and private sector companies.

"Snowdon provides a unique solution to the problems of efficiency and productivity in drug discovery by integrating advanced tools with proprietary information technology to efficiently discover new drugs," noted James M. Golubieski, president of Foundation Venture Capital Group. "This battery of proprietary computational tools can rapidly identify high-value molecules that can be used for initial biological proof of concept evaluation studies."

An article that features the company's novel Fragment-Based Shape Signatures tool was recently published in the December 2013 issue of the Journal of Computer-Aided Molecular Design (http://goo.gl/0E2NNX).

For more information, contact Mr. Golubieski  at (908) 731-6601 or [email protected]  Or, visit www.foundationventure.com.

About Foundation Venture Capital Group

Foundation Venture Capital Group, LLC, (www.foundationventure.com) invests in life science start-up companies in New Jersey that want to move their products and ideas to commercialization.   In addition to Snowdon, FVCG portfolio companies currently include: 

  • Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies such as leukemia and lymphomas;
  • Affineti Biologics, Inc.,  advancing research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine;
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
  • Durin Technologies, working to develop a blood test to diagnose Alzheimer's, Parkinson's and other neurodegenerative diseases;
  • GeneAssess, Inc.,  developing a diagnostic tool for more accurate breast cancer staging;
  • Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm);
  • MentiNova, Inc., working to reduce side effects of L-Dopa Induced Dyskinesia
  • NovoPedics, Inc., developing an implantable meniscus replacement/regeneration medical device to restore mobility to patients suffering from severe meniscus knee injuries

SOURCE Foundation Venture Capital Group

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...